^
    Back
    Association details:
    Biomarker:BRAF V600
    Cancer:Ganglioglioma
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Melanoma)
    New
    Title:

    trametinib (Mekinist®) is accepted for restricted use within NHSScotland.

    Excerpt:
    trametinib (Mekinist) is accepted for restricted use within NHSScotland....in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Neurology
    Title:

    Sustained Tumor Control With MAPK Inhibition in BRAF V600–Mutant Adult Glial and Glioneuronal Tumors

    Published date:
    06/04/2021
    Excerpt:
    Twenty-eight adults with recurrent or disseminated BRAF V600-mutant gangliogliomas (n=9), pleomorphic xanthoastrocytomas (n=9), and diffuse gliomas...15 combinations of RAFi/MEKi [vemurafenib+cobimetinib (n=5), dabrafenib+trametinib...Eleven patients achieved a partial or complete response (11/28, 39%), with a median reduction of -78% in their tumor burden....Five patients were rechallenged with RAFi/MEKi at progression, with novel tumor responses in two....study highlights the clinical benefits of RAFi/MEKi in adult patients with BRAF-mutant GGNT...
    DOI:
    https://doi.org/10.1212/WNL.0000000000012330